Testosterone propionate

Testosterone propionate
Clinical data
Trade names Agrovirin, Andronate, Andrusol-P, Masenate, Neo-Hombreol, Oreton, Perandren, Synandrol, Testoviron, numerous others
Routes of
Intramuscular injection
Synonyms NSC-9166
CAS Number 57-85-2
PubChem (CID) 5995
DrugBank DB01420
ChemSpider 5774
KEGG D00959
Chemical and physical data
Formula C22H32O3
Molar mass 344.50 g·mol−1
3D model (Jmol) Interactive image

Testosterone propionate (USAN, BAN) (brand names Agrovirin, Andronate, Andrusol-P, Masenate, Neo-Hombreol, Oreton, Perandren, Synandrol, Testoviron, numerous others), or testosterone propanoate, also known as propionyltestosterone, is an androgen and anabolic steroid and a testosterone ester.[1][2][3][4] Testosterone esters were synthesized for the first time in 1936, and were found to have greatly improved potency relative to testosterone.[5] Among the esters synthesized, testosterone propionate was the most potent, and for this reason, was selected for further development, subsequently being marketed.[5] Along with testosterone enanthate, testosterone cypionate, and testosterone undecanoate, testosterone propionate is one of the most widely used testosterone esters.[6]

Testosterone propionate was introduced in 1937 by Schering AG in Germany under the brand name Testoviron.[7] It was the first ester of testosterone to be introduced,[8] and was the major form of testosterone used medically before 1960.[7] In the 1950s, longer-acting testosterone esters like testosterone enanthate and testosterone cypionate were introduced and superseded testosterone propionate.[8] Although rarely used nowadays due to its short duration,[9] testosterone propionate remains medically available and is still marketed in the United States.[7][10]

See also


  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–642. ISBN 978-1-4757-2085-3.
  2. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. ISBN 978-3-88763-075-1.
  3. I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. ISBN 978-94-011-4439-1.
  4. Eric Wentworth Martin; William John Husa (1971). Dispensing of medication: a manual on the formulation of pharmaceutical products, the dispensing of prescriptions, and the professional practice of pharmacy. Mack Pub. Co. p. 328.
  5. 1 2 Korenchevsky V, Dennison M, Eldridge M (1937). "The prolonged treatment of castrated and ovariectomized rats with testosterone propionate". Biochem. J. 31 (3): 475–85. doi:10.1042/bj0310475. PMC 1266958Freely accessible. PMID 16746360.
  6. Kicman, A T (2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. ISSN 0007-1188.
  7. 1 2 3 William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 413,426,607. ISBN 978-0-9828280-1-4.
  8. 1 2 Eberhard Nieschlag; Hermann M. Behre; Susan Nieschlag (26 July 2012). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 9–. ISBN 978-1-107-01290-5.
  9. Christopher R. Chapple; William D. Steers (10 May 2011). Practical Urology: Essential Principles and Practice: Essential Principles and Practice. Springer Science & Business Media. pp. 228–. ISBN 978-1-84882-034-0.
  10. "Drugs@FDA: FDA Approved Drug Products" (HTML). United States Food and Drug Administration. Retrieved 16 November 2016.

This article is issued from Wikipedia - version of the 11/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.